Smith Group Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Smith Group Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-106,651	Closed	-$705K	–	419
2015 Q1	$705K	Sell	106,651 -8,758	-8%	-$59.8K	0.02%	189
2014 Q4	$735K	Buy	+115,409	New	+$930K	0.03%	192
2013 Q4	–	Sell	-69,330	Closed	-$1.16M	–	417
2013 Q3	$1.16M	Sell	69,330 -7,164	-9%	-$120K	0.05%	171
2013 Q2	$1.16M	Buy	+76,494	New	+$1.16M	0.05%	178

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return

Smith Group Asset Management's LXRX Position: Q2 2015 in Review

Smith Group Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2015, closing a stake of 106,651 shares — an estimated $705K sold.

Smith Group Asset Management first reported a position in LXRX in Q2 2013 and held it in 4 quarters. The position peaked at $1.16M in Q2 2013. 94 funds tracked by Wall St. Rank hold LXRX as of Q2 2015.

Smith Group Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Smith Group Asset Management sold 106,651 Lexicon Pharmaceuticals shares in Q2 2015, an estimated $705K.
Smith Group Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Smith Group Asset Management's Lexicon Pharmaceuticals position peaked at $1.16M in Q2 2013.
94 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2015.

Based on Smith Group Asset Management's 13F filing for Q2 2015, filed 29 Jul 2015.